Meeting
2022 ASCO Annual Meeting
Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms.
Authors
Sukhmani Kaur Padda
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
Sukhmani Kaur Padda , Rahul Raj Aggarwal , Arya Ashok , Elizabeth Mauer , Maryam Shirazi , Emily K. Bergsland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2625)
DOI
10.1200/JCO.2022.40.16_suppl.2625
Abstract #
2625
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).
First Author: Alberto Puccini
Poster
2024 ASCO Annual Meeting
Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.
First Author: Pushkar Mutha
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
First Author: Cody Eslinger
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Survival of patients with microsatellite instability-high and Lynch syndrome-associated pancreatic ductal adenocarcinomas.
First Author: Naaz Nasar